The most recent medication that has been approved for weight management by the TGA is a combined GLP1-GIP agonist. This medication has been approved in Australia for over a year for the treatment of Type 2 Diabetes.
With regards to reducing the risk of developing Type 2 Diabetes in patients who have overweight or obesity, this new medication has been shown to reduce this risk by 94%!
GIP/GLP-1 receptor agonists work by activating two incretin hormone receptors. GLP-1 is a regulator of appetite and caloric intake. Nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake.
In treating metabolic disease, this is revolutionary. For patients to be able to avoid progression to Type 2 Diabetes is beyond incredible! For more details, check out the Eli Lilly SURMOUNT-1 Phase 3 study.
